Our preclinical studies using PDXs also showed that combined treatment with mTORC1 inhibitor and FIN synergistically depleted GPX4 and induced ferroptosis in vivo, resulting in more potent tumor growth suppression than either treatment alone. The gene discussed is GPX4; the disease is neoplasm.